Push to detect Alzheimer’s earlier
Treatments to halt or reverse Alzheimer's disease remain elusive, but researchers reported progress Sunday in early diagnosis, including the use of a chemical marker, visible via brain scan, to detect substances associated with the disease. Other researchers are working on less invasive techniques, such as measuring physical or sensory changes to smell and vision that occur during early stages of the disease. In one study, scientists are gauging the width of blood vessels in the retina. The data were presented Sunday at the Alzheimer's Association International Conference on Alzheimer's Disease. Among the possible advances in early detection are chemical tracers, some of which tag clumps of a sticky substance in the brain called amyloid, and others that mark amyloid and a protein called tau—both thought to contribute to the disease. These tracers make Alzheimer's pathology visible in a living brain, which until now could only be seen upon autopsy. The new findings show the presence of amyloid on a PET scan might lead to greater memory loss or other cognitive troubles.
- Urologists 'Outraged' Over PSA Test Challenge
- New Facebook Page Gathers Stories of Medical Harm
- Luxury Hospital Facilities Put Patient Experience First
- Five Hospitals Share Three Secrets to Improve Knee Surgery Outcomes
- Heartland Health Joins Mayo Clinic Network
- Beleaguered Fairview Health CEO to Retire in July
- Health Insurance Exchanges Put Defined Benefits to the Test
- Challenging Physicians to Help Improve the ED
- For hospitals and insurers, new fervor to cut costs
- The Power of Plugged-In Physicians

